BVF Partners IVEVF Position
Active4-Fund ConvergenceBVF Partners held their position in Inventiva S.A. (IVEVF) in Q4 2025, holding $3.2M worth of shares across 686,040 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
IVEVF is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Full company profile →BVF Partners IVEVF Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 686,040 | — | $3.2M |
| Q3 2025 | Held | 686,040 | — | $4.0M |
| Q2 2025 | Held | 686,040 | — | $2.1M |
| Q1 2025 | Held | 686,040 | — | $2.1M |
| Q4 2024 | Held | 686,040 | — | $1.5M |
| Q3 2024 | Held | 686,040 | — | $1.3M |
| Q2 2024 | Held | 686,040 | — | $2.0M |
| Q1 2024 | Held | 686,040 | — | $2.5M |
| Q4 2023 | Held | 686,040 | — | $3.1M |
| Q3 2023 | Held | 686,040 | — | $2.9M |
| Q2 2023 | Held | 686,040 | — | $2.8M |
| Q1 2023 | New | 686,040 | +686,040 | $2.5M |
Frequently Asked Questions
Does BVF Partners own IVEVF?
Yes. As of Q4 2025, BVF Partners holds 686,040 shares of Inventiva S.A. (IVEVF) valued at $3.2M. This data comes from their SEC 13F filing.
How many hedge funds own IVEVF?
4 specialist biotech hedge funds currently hold IVEVF, including RTW Investments, Deep Track Capital, Eventide Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy IVEVF?
BVF Partners's position in IVEVF was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's IVEVF position increasing or decreasing?
BVF Partners held their IVEVF position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IVEVFCompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →